Premium
Cellular and humoral immune response to a third generation hepatitis B vaccine
Author(s) -
Schumann A.,
Fiedler M.,
Dahmen U.,
GrosseWilde H.,
Roggendorf M.,
Lindemann M.
Publication year - 2007
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.2007.00848.x
Subject(s) - elispot , vaccination , immunogenicity , immunology , medicine , immunization , cellular immunity , immune system , hepatitis b virus , immunity , hepatitis b , humoral immunity , virology , hepatitis b vaccine , t cell , virus , hbsag
Summary. Liver transplantation is often the ultimate option of therapy for chronically hepatitis B virus (HBV) infected patients. Adoptive transfer of HBV immunity with the liver after vaccination of living liver donors (LLD) could be a new approach to prevent reinfection in the recipients. The time to achieve HBV immunity in LLD is usually short (1–2 months). Therefore, we established a short time immunization protocol (four injections in 2 weeks intervals) using Hepimmune, a recombinant vaccine that contains the L, M and S proteins of HBV. We examined cellular and humoral immune responses after immunization with Hepimmune and compared its immunogenicity to that of a standard HBV vaccine containing only the S protein (HBVAXPRO ® ). Cellular immunity was measured by interferon (IFN)‐ γ ELISpot and proliferation assay. HBV‐specific T cells were detectable in the Hepimmune group after the second and in the standard group after the third vaccination. IFN‐ γ production of T cells was significantly higher ( P < 0.001) after the third vaccination with Hepimmune. Proliferative responses were also significantly ( P < 0.01) higher in the Hepimmune group after the second to fourth vaccination. The humoral immune response could already be detected after the first immunization in nine of 15 Hepimmune vaccinated test persons while it was only observed in one of 15 probands of the later group. Titres differed significantly ( P < 0.01) following all four vaccinations. Thus, Hepimmune appears to be a good candidate for short time immunization protocols.